Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
Lapi F, Cipriani F, Caputi AP, Corrao G, Vaccheri A, Sturkenboom MC, Di Bari M, Gregori D, Carle F, Staniscia T, Vestri A, Brandi M, Fusco V, Campisi G, Mazzaglia G; Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group.
Lapi F, et al.
Osteoporos Int. 2013 Feb;24(2):697-705. doi: 10.1007/s00198-012-2013-y. Epub 2012 May 23.
Osteoporos Int. 2013.
PMID: 22618266